...
首页> 外文期刊>Radiation Physics and Chemistry >Dosimetric evaluation of Sm-153-EDTMP, Lu-177-EDTMP and Ho-166-EDTMP for systemic radiation therapy: Influence of type and energy of radiation and half-life of radionuclides
【24h】

Dosimetric evaluation of Sm-153-EDTMP, Lu-177-EDTMP and Ho-166-EDTMP for systemic radiation therapy: Influence of type and energy of radiation and half-life of radionuclides

机译:全身放射疗法的Sm-153-EDTMP,Lu-177-EDTMP和Ho-166-EDTMP的剂量学评估:辐射类型和能量以及放射性核素半衰期的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In radiopharmaceutical therapy, delivered doses to critical organs must be below a certain threshold therefore internal radiation dosimetry of radiopharmaceuticals is essential. Advantages and disadvantages of radionuclides with different characteristics were evaluated for selection of appropriate radionuclide. The Monte Carlo MCNPX simulation program was used to obtain radial dose and cumulative dose of Sm-153, Lu-177 and Ho-166 used in radiotherapy of bone metastases. A cylindrical geometry with constant density materials was supposed for simulation of femur bone. The radius of bone marrow, bone, and surrounding soft tissue was considered 0.6 cm, 1.3 cm and 4 cm, respectively. It was assumed that the radionuclides were uniformly distributed throughout the tumor. "continuous energy spectrum" of beta particle was used instead of mean beta energy. Our simulations show that absorbed dose in target organ (bone) is greater than other organs and Ho-166 gives a higher dose to the critical organ of bone marrow than either Sm-153 or Lu-177. Absorbed dose versus time demonstrate faster dose delivery for the short half-life radionuclides (Sm-153 and Ho-166). These results are in good agreement with clinical observations which show a pain relief within 1 week after intravenous administration of Sm-153-EDTMP, whereas it occurs within 2 week in the case of Lu-177-EDTMP. According to the results, combination of different radionuclides with different characteristics such as Sm-153-EDTMP and Lu-177-EDTMP could be more advantageous to patients with painful bone metastasis. (C) 2014 Elsevier Ltd. All rights reserved.
机译:在放射性药物治疗中,输送至关键器官的剂量必须低于某个阈值,因此放射性药物的内部辐射剂量法必不可少。评价了具有不同特性的放射性核素的优缺点,以选择合适的放射性核素。使用Monte Carlo MCNPX模拟程序来获得放射剂量和骨转移放射治疗中使用的Sm-153,Lu-177和Ho-166的累积剂量。假定使用具有恒定密度材料的圆柱几何形状来模拟股骨。骨髓,骨骼和周围软组织的半径分别被认为是0.6 cm,1.3 cm和4 cm。假定放射性核素均匀地分布在整个肿瘤中。使用β粒子的“连续能谱”代替平均β能量。我们的模拟结果表明,目标器官(骨骼)的吸收剂量大于其他器官,Ho-166对骨髓的关键器官的剂量高于Sm-153或Lu-177。吸收剂量与时间的关系表明,短半衰期放射性核素(Sm-153和Ho-166)的给药速度更快。这些结果与临床观察结果非常吻合,后者显示静脉内注射Sm-153-EDTMP后1周内疼痛缓解,而对于Lu-177-EDTMP则在2周内出现疼痛缓解。根据结果​​,将具有不同特性的不同放射性核素(如Sm-153-EDTMP和Lu-177-EDTMP)组合起来对骨痛转移患者可能更有利。 (C)2014 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号